Hepatocellular carcinoma (HCC) is linked to immunosuppression. Relieving immunosuppression has been an attractive strategy to improve the efficacy of cancer immunotherapy. Peptidoglycan recognition protein 2 (PGLYRP2) is a pattern recognition receptor which is specifically expressed in liver and implicated in the regulation of innate immunity and immunosurveillance. However, the role of hepatic PGLYRP2 in modulating immune responses against HCC remains to be investigated.

中文翻译：

---

肿瘤衍生的 PGLYRP2 预测肝细胞癌的存活率和抗肿瘤免疫反应

肝细胞癌 (HCC) 与免疫抑制有关。解除免疫抑制一直是提高癌症免疫疗法疗效的有吸引力的策略。肽聚糖识别蛋白 2 (PGLYRP2) 是一种模式识别受体，在肝脏中特异性表达，参与先天免疫和免疫监视的调节。然而，肝脏 PGLYRP2 在调节针对 HCC 的免疫反应中的作用仍有待研究。